Welcome to our BioDeals update for the last week. Here we summarise fund raising, licencing deals and more across Newton Colmore’s key markets; medical devices and biotechnology.
Sanofi pays $600M upfront for Dren Bio’s bispecific in latest immunology play
British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together.
Sibel Health, an award-winning medical technology company, is pleased to announce the closing of $30 million in new equity financing.
Thena Capital, a UK-based early-stage medical technology investor, has launched its Fund I with a first close at £27m. The fund will invest across the UK early-stage MedTech landscape, backing founders in areas such as oncology, chronic conditions, cardiovascular, neurology, mental health, care service delivery, and women’s health.
Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones.
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
Clinical trial tech company Clario has sealed its second acquisition in a week, doubling down further on neuroscience by picking up imaging specialist NeuroRx.
University of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.
Sofinnova Partners has raised €165m within its biotech acceleration fund Biovelocita II that attracted investments fromBig Pharma including Amgen, Bristol Myers Squibb, and Pfizer Ventures.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.